Abstract
Bleeding remains a potential complication for patients requiring extracorporeal life support systems. Recombinant activated factor VII (rFVIIa) is one of the drugs used in controlling bleeding. Its use is generally found to be safe. We report a paediatric patient who developed fatal thrombosis with the use of rFVIIa whilst on extracorporeal membrane oxygenation and discuss the possible factors that lead to fatal thrombosis. Crown
Original language | English (US) |
---|---|
Pages (from-to) | 685-686 |
Number of pages | 2 |
Journal | European Journal of Cardio-thoracic Surgery |
Volume | 34 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2008 |
Externally published | Yes |
Keywords
- Bleeding
- Extracorporeal membrane oxygenation
- Thrombosis
ASJC Scopus subject areas
- Surgery
- Pulmonary and Respiratory Medicine
- Cardiology and Cardiovascular Medicine